Zynerba Pharmaceuticals
Manufacturing · Pennsylvania, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
80 Lancaster Ave Ste 300, Devon, Pennsyl...Phone Number
(484) 581-7505Website
www.zynerba.comRevenue
<$5 MillionIndustry
About Zynerba Pharmaceuticals
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.Explore more
Zynerba Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Zynerba Pharmaceuticals
Compare insights from companies similar to Zynerba Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Zynerba Pharmaceuticals
<$5M
11-50
Private
$149.2M
2014
JA
Joseph ApostolicoVice President, Human Resources
Zynerba Pharmaceuticals Tech Stack
A closer look at the technologies used by Zynerba Pharmaceuticals
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Zynerba Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for tran... Read More
